Today, MAPS has announced that its second Phase 3 trial of MDMA-assisted therapy (MDMA-AT) for PTSD confirms prior positive results. The nonprofit shared few details in its Thursday press release, reproduced below, but did note that no serious adverse events were observed. In MAPS’ first Phase 3 study, three serious adverse events were reported among two participants in the placebo group.
Source